Enzymotec Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Enzymotec Ltd with three other
pharmaceutical manufacturers in Middle East:
Alexandria Pharmaceuticals and Chemical Industries Co
sales of 424.96 million Egyptian Pounds [US$23.98 million]
Dar Al Dawa Development & Investment
(60.88 million Jordanian Dinars [US$85.74 million]
of which 80%
was Pharmaceuticals), and
Glaxo Smith Kline
based in Egypt
(1.17 billion Egyptian Pounds [US$65.78 million]
of which 93%
was Medical Sector).
During the year ended December of 2016, sales at
Enzymotec Ltd were 182.39 million Israel Shekels (US$53.47 million).
decrease of 6.9%
versus 2015, when the company's sales were 195.82 million Israel Shekels.
Contributing to the drop in overall sales was the 9.8% decline
in Nutrition, from 210.48 million Israel Shekels to 189.90 million Israel Shekels.
However, these declines were partially offset by the increase in sales of
Vaya Pharma (up 30.3% to 42.88 million Israel Shekels)